1 |
|
Macular Thickening by OCT In a Phase III Trial of Fingolimod: The Importance of Quality Control | Winges, Kimberly; Cello, Kimberly; Werner, John; Calabresi, Peter; Balcer, Laura; Keltner, John | Cystoid macular edema was documented in a small number of MS patients taking fingolimod (Gilenya, Novartis) in sentinel clinical trials. FDA concern about vision risk has led to a recent statement by the AAO and NANOS, which recommends ophthalmoscopic screening at initiation and followup. | 20120214_nanos_sciplatform_07 |